Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone203-304-2499
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees15
Next Earnings Date2/13/2020 (Estimated)
OptionableNot Optionable
Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions
What is Trevi Therapeutics' stock symbol?
Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."
How were Trevi Therapeutics' earnings last quarter?
Trevi Therapeutics Inc (NASDAQ:TRVI) issued its quarterly earnings data on Thursday, November, 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.07. View Trevi Therapeutics' Earnings History.
When is Trevi Therapeutics' next earnings date?
What price target have analysts set for TRVI?
5 equities research analysts have issued twelve-month target prices for Trevi Therapeutics' stock. Their forecasts range from $14.00 to $20.00. On average, they anticipate Trevi Therapeutics' stock price to reach $16.75 in the next year. This suggests a possible upside of 214.3% from the stock's current price. View Analyst Price Targets for Trevi Therapeutics.
What is the consensus analysts' recommendation for Trevi Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevi Therapeutics.
Has Trevi Therapeutics been receiving favorable news coverage?
News articles about TRVI stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trevi Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Trevi Therapeutics.
Are investors shorting Trevi Therapeutics?
Trevi Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 37,500 shares, an increase of 72.8% from the December 15th total of 21,700 shares. Based on an average trading volume of 14,000 shares, the short-interest ratio is currently 2.7 days. Currently, 1.5% of the company's shares are sold short. View Trevi Therapeutics' Current Options Chain.
Who are some of Trevi Therapeutics' key competitors?
Some companies that are related to Trevi Therapeutics include Puma Biotechnology (PBYI), Evolus (EOLS), Avid Bioservices (CDMO), Spectrum Pharmaceuticals (SPPI), Recro Pharma (REPH), Syros Pharmaceuticals (SYRS), OptiNose (OPTN), Cue Biopharma (CUE), Stemline Therapeutics (STML), 89bio (ETNB), Satsuma Pharmaceuticals (STSA), CytomX Therapeutics (CTMX), INDIVIOR PLC/S (INVVY), Galera Therapeutics (GRTX) and Kalvista Pharmaceuticals (KALV).
What other stocks do shareholders of Trevi Therapeutics own?
Who are Trevi Therapeutics' key executives?
Trevi Therapeutics' management team includes the folowing people:
- Ms. Jennifer L. Good, Co-Founder, CEO, Pres & Director (Age 54)
- Mr. Thomas R. Sciascia, Co-Founder and Chief Medical Officer (Age 66)
- Mr. Christopher J. Seiter, Chief Financial Officer (Age 52)
- Dr. Helena Brett-Smith M.D., Chief Devel. Officer (Age 62)
- Dr. Amale Hawi, Sr. VP of CMC (Age 65)
When did Trevi Therapeutics IPO?
(TRVI) raised $70 million in an IPO on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.
How do I buy shares of Trevi Therapeutics?
Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Trevi Therapeutics' stock price today?
One share of TRVI stock can currently be purchased for approximately $5.33.
How big of a company is Trevi Therapeutics?
What is Trevi Therapeutics' official website?
How can I contact Trevi Therapeutics?
Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at 203-304-2499 or via email at [email protected]
MarketBeat Community Rating for Trevi Therapeutics (NASDAQ TRVI)
MarketBeat's community ratings are surveys of what our community members think about Trevi Therapeutics and other stocks. Vote "Outperform" if you believe TRVI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVI will underperform the S&P 500 over the long term. You may vote once every thirty days.
